Now, it’s worth noting Stock Advisor’s total average return is 981 % — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area. The company should ...

Orange juice has fallen on semi-hard times recently, with weather- and disease-caused crop reductions, a significant drop in U.S. consumption and the pressure of inflation on household budgets, all ...

Gene therapy is not without its risks: patients have died from liver failure to catastrophic inflammatory responses to ...

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch ...

The innovative drug sector is emerging as a new driver of export growth, fueled largely by cross-border out-licensing, with the NewCo model and direct overseas commercialization also gaining traction, ...

Breakthrough Properties, a premier global life science real estate developer, today announced it has acquired a recently ...

Eton all but doubled its sales year over year -- 99% growth -- and flipped from a $0.10 per share GAAP loss to a $0.35 per ...

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global ...

VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for ...

Eton Pharmaceuticals, Inc. posts record Q2 2026 results, raises revenue guidance, targets $500M peak sales & 35%+ EBITDA ...

A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with ...